<DOC>
	<DOCNO>NCT02452905</DOCNO>
	<brief_summary>Bronchiolitis extremely common cause respiratory illness infant cause viral infection.This study evaluate whether treatment nitazoxanide ( NTZ ) reduce duration severity respiratory symptom cause bronchiolitis . Half participant receive NTZ half receive placebo .</brief_summary>
	<brief_title>Finding Better Treatment Bronchiolitis : A Clinical Trial Oral Nitazoxanide Treatment Bronchiolitis Infants Presenting Hospital Emergency Departments</brief_title>
	<detailed_description>Nitazoxanide ( NTZ ) novel anti-infective medication licence use United States ( US ) , include child infant treat infection . It thiazolide class antimicrobial show vitro and/or clinical activity broad spectrum pathogen , include range virus , parasite bacteria . This study determine whether NTZ effective empirical treatment bronchiolitis . It also help u understand effect NTZ amount virus present viral load change course disease . If study show NTZ useful treatment , large study conduct enrol infant present primary care facility .</detailed_description>
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Bronchiolitis</mesh_term>
	<mesh_term>Nitazoxanide</mesh_term>
	<criteria>Aged great equal 1 month less equal 12 month Diagnosed bronchiolitis assess doctor Parent/legally responsible carer provide informed consent infant/child participate study Parent/legally responsible carer able willing comply requirement protocol Parent/legally responsible carer willing attend study follow visit study day 3 infant/child previously discharge hospital Parent/legally responsible carer willing allow party involve treatment child ( include general practitioner , paediatrician , hospital medical nursing staff , community clinic staff ) notify participation trial Infants child whose parent willing allow study team obtain interim medical history participant electronic medical record ( include immunisation record ) and/or participant general practitioner medical professional period enrolment study day 180 Presence symptom bronchiolitis ( breathe difficulty , difficulty feeding , cough , poor feeding ) great equal 48 hour time enrolment Born gestational age le 32 week Has history condition associate risk severe bronchiolitis include ( significant cardiovascular disease , include congenital heart disease , significant respiratory disease include chronic lung disease , Trisomy 21 , significant neurological disease include history seizure disorder , significant impairment/alteration immune system include congenital immunodeficiency disorder consider relevant medically qualified investigator Requiring admission intensive care unit enrolment Clinical suspicion illness bronchiolitis Contraindication study drug placebo ( hypersensitivity ) , medical treatment medication opinion admit team would make child unsuitable study Receipt investigational drug/vaccine , drug use study within 30 day prior receive first dose NTZ plan use study period 1 month administration final dose NTZ Previously enrol study Parent le 18 year age TEMPORARY EXCLUSION CRITERIA Receipt antiviral medication within previous 7 day Inability tolerate either oral nasogastric route ( e.g . ileus ) Any systemic corticosteroid ( equivalent ) treatment 14 day prior enrolment</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>